The Anticancer Potential of Doxycycline and Minocycline-A Comparative Study on Amelanotic Melanoma Cell Lines
Malignant melanoma is still a serious medical problem. Relatively high mortality, a still-growing number of newly diagnosed cases, and insufficiently effective methods of therapy necessitate melanoma research. Tetracyclines are compounds with pleiotropic pharmacological properties. Previously published studies on melanotic melanoma cells ascertained that minocycline and doxycycline exerted an anti-melanoma effect. The purpose of the study was to assess the anti-melanoma potential and mechanisms of action of minocycline and doxycycline using A375 and C32 human amelanotic melanoma cell lines. The obtained results indicate that the tested drugs inhibited proliferation, decreased cell viability, and induced apoptosis in amelanotic melanoma cells. The treatment caused changes in the cell cycle profile and decreased the intracellular level of reduced thiols and mitochondrial membrane potential. The exposure of A375 and C32 cells to minocycline and doxycycline triggered the release of cytochrome c and activated initiator and effector caspases. The anti-melanoma effect of analyzed drugs appeared to be related to the up-regulation of ERK1/2 and MITF. Moreover, it was noticed that minocycline and doxycycline increased the level of LC3A/B, an autophagy marker, in A375 cells. In summary, the study showed the pleiotropic anti-cancer action of minocycline and doxycycline against amelanotic melanoma cells. Considering all results, it could be concluded that doxycycline was a more potent drug than minocycline.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
International journal of molecular sciences - 23(2022), 2 vom: 13. Jan. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rok, Jakub [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antineoplastic Agents |
---|
Anmerkungen: |
Date Completed 03.02.2022 Date Revised 03.02.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/ijms23020831 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335896626 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335896626 | ||
003 | DE-627 | ||
005 | 20231225230911.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/ijms23020831 |2 doi | |
028 | 5 | 2 | |a pubmed24n1119.xml |
035 | |a (DE-627)NLM335896626 | ||
035 | |a (NLM)35055021 | ||
035 | |a (PII)831 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rok, Jakub |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Anticancer Potential of Doxycycline and Minocycline-A Comparative Study on Amelanotic Melanoma Cell Lines |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.02.2022 | ||
500 | |a Date Revised 03.02.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Malignant melanoma is still a serious medical problem. Relatively high mortality, a still-growing number of newly diagnosed cases, and insufficiently effective methods of therapy necessitate melanoma research. Tetracyclines are compounds with pleiotropic pharmacological properties. Previously published studies on melanotic melanoma cells ascertained that minocycline and doxycycline exerted an anti-melanoma effect. The purpose of the study was to assess the anti-melanoma potential and mechanisms of action of minocycline and doxycycline using A375 and C32 human amelanotic melanoma cell lines. The obtained results indicate that the tested drugs inhibited proliferation, decreased cell viability, and induced apoptosis in amelanotic melanoma cells. The treatment caused changes in the cell cycle profile and decreased the intracellular level of reduced thiols and mitochondrial membrane potential. The exposure of A375 and C32 cells to minocycline and doxycycline triggered the release of cytochrome c and activated initiator and effector caspases. The anti-melanoma effect of analyzed drugs appeared to be related to the up-regulation of ERK1/2 and MITF. Moreover, it was noticed that minocycline and doxycycline increased the level of LC3A/B, an autophagy marker, in A375 cells. In summary, the study showed the pleiotropic anti-cancer action of minocycline and doxycycline against amelanotic melanoma cells. Considering all results, it could be concluded that doxycycline was a more potent drug than minocycline | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a ERK1/2 | |
650 | 4 | |a LC3A/B | |
650 | 4 | |a MITF | |
650 | 4 | |a apoptosis | |
650 | 4 | |a caspases | |
650 | 4 | |a cell cycle | |
650 | 4 | |a doxycycline | |
650 | 4 | |a melanoma | |
650 | 4 | |a minocycline | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a Caspases |2 NLM | |
650 | 7 | |a EC 3.4.22.- |2 NLM | |
650 | 7 | |a Minocycline |2 NLM | |
650 | 7 | |a FYY3R43WGO |2 NLM | |
650 | 7 | |a Doxycycline |2 NLM | |
650 | 7 | |a N12000U13O |2 NLM | |
700 | 1 | |a Rzepka, Zuzanna |e verfasserin |4 aut | |
700 | 1 | |a Kowalska, Justyna |e verfasserin |4 aut | |
700 | 1 | |a Banach, Klaudia |e verfasserin |4 aut | |
700 | 1 | |a Beberok, Artur |e verfasserin |4 aut | |
700 | 1 | |a Wrześniok, Dorota |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 23(2022), 2 vom: 13. Jan. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2022 |g number:2 |g day:13 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms23020831 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2022 |e 2 |b 13 |c 01 |